A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

NCT01301092 · Completed

Last updated 2026-05-28

This study compares how the diabetes medication LY2189265 is absorbed in the body when given as an injection under the skin versus directly into the vein in healthy volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18+ · all sexes Healthy volunteers accepted.

Timeline Started 2011-02 · est. completion 2011-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01301092 ↗

Description as written by the study sponsor.

LY2189265 is an investigational drug being developed for the treatment of type 2 diabetes mellitus. This study will compare the concentrations of LY2189265 using different methods of administration: subcutaneous (or SC- an injection just under the skin), intravenous (or IV - into a vein in the arm) and intramuscular (IM - into the muscle of the left thigh). The purpose of this study is to look at how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given by the methods above. The study is divided into three parts, Part A, B and C. Volunteers will only be able to participate in one part. All Participants in Part A will receive a single IV dose of up to 0.1 milligram (mg). Participants in Part B will be given drug twice by IV and an SC injection (1.5 mg). Part B of the study will occur after Part A because the dose of IV drug will depend on the results of Part A. Part B of the study may not occur if the volunteers in Part A do not tolerate the drug. Participants in Part C will also be given drug twice by an SC injection and an IM injection, both doses will be 0.75 mg.

Treatments tested

LY2189265 Biologic

administered intravenous, subcutaneous or intramuscular

Main thing measured	Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type II
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01301092 ↗